Frits van Rhee
Professor
Also affiliated: University of North Carolina at Chapel Hill (2013); Fox Chase Cancer Center (2006–2013); Memorial Hospital of South Bend (2000–2001); National Institutes of Health (1997–1999); NewYork–Presbyterian Hospital (2013); Central South University (2023); University of South Carolina (2000–2004); Bon Secours Health System (2011); University of Basel (2005); Medical College of Wisconsin (2024); Cornell University (2006–2013); University of Arkansas Medical Center (2014–2023); Anthony Nolan (2001–2002); Aberdeen Royal Infirmary (1995); The Royal Free Hospital (2002); Southmead Hospital (1995); Hammersmith Hospital (1995–2001); John Radcliffe Hospital (1992); Palmetto Health Richland (2000–2001); Westmead Hospital (1995); Blood Cancer UK (1994–2000); Fred Hutch Cancer Center (2013); MUSC Hollings Cancer Center (2000); Cancer Research And Biostatistics (2005–2015); South Carolina Cancer Alliance (2001–2002); National Heart Lung and Blood Institute (1997–2001); Queen Elizabeth Hospital (1990); Leuka (1994–1995); Hopp Children's Cancer Center Heidelberg (2022); Dana-Farber Cancer Institute (2003); Myeloma UK (2007–2018); Little Flower Hospital & Research Centre (2023); Winthrop Rockefeller Foundation (2013–2026); Queen's Medical Centre (1991); Third Xiangya Hospital (2023); Children's Cancer and Leukaemia Group (1995); International Myeloma Foundation (2015); Best Biotech (2009); Southwestern Medical Center (2000); University College London (2002); University of Pennsylvania (2013); The University of Texas Southwestern Medical Center (2000)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. Frits van Rhee's research focuses on the immunotherapy of multiple myeloma and Castleman's Disease. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research at the University of Arkansas for Medical Sciences, where he also directs developmental and translational medicine within the Myeloma Institute for Research and Therapy.
His work includes investigating the molecular underpinnings of multiple myeloma, such as its evolutionary pathways from smoldering myeloma to advanced disease, and characterizing its immune microenvironment at a single-cell level. Dr. van Rhee has also published on the definition and prognosis of the TAFRO clinical subtype of idiopathic multicentric Castleman's disease. His research explores emerging treatments, including bispecific antibodies and CAR-T cell therapy, and examines associated risks like infections and disparities in access to clinical trials.
With a significant publication record of over 800 manuscripts and a high citation count, Dr. van Rhee is recognized as a highly cited researcher. He is also a member of several prominent international societies in hematology and cellular therapy and serves on the editorial boards of multiple hematology journals. His scholarly output includes research on genomic classification, prognostication in multiple myeloma, and real-world studies of therapeutic agents.
Research Overview
Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute
Metrics
- h-index: 83
- Publications: 850
- Citations: 26,646
Selected Publications
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
Testicular plasmacytoma: A comprehensive case series and review. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist’s perspective (2025)
-
Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease (2025)
-
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)
-
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies. (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
Grants & Funding
As listed on this researcher's institutional profile.
- Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438 United BioSource Corporation Principal Investigator
- UARK 2006-41 A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal lgG1 antibody) in Subjects with Adva Protein Design Labs, Inc Principal Investigator
- UARK 2004-61: (AMD3100-3102) A Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 ug/kg) plus G-CSF (10 ug/k AnorMED, Inc. Principal Investigator
- 2004-23: (Protocol C0328T03) A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Administered Biweekly as an Intravenous Infusion Centocor, Inc. Principal Investigator
- KAG 301-Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (Kos 953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Genzyme Principal Investigator
- UARK# 2012-02 TOTAL THERAPY 5B: A PHASE II TRIAL FOR HIGH-RISK MYELOMA EVALUATING Onyx Pharmaceuticals, Inc. Principal Investigator
- A Randomized, Double blind, Placebo controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportiv Centocor, Inc. Principal Investigator
- Protocol CNTO328MCD2002; Phase 2, An Open-label, Multicenter Study to Evaluate th Centocor, Inc. Principal Investigator
- UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
- S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct...260489 NIH/Nat. Cancer Institute via SouthWest Oncology Group Principal Investigator
- JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target NIH/Nat. Heart, Lung & Blood Institute via University of Pennsylvania Principal Investigator
- KIR-Ligand Mismatched Natural Killer Cell Therapy for Myeloma Multiple Myeloma Research Foundation Principal Investigator
- Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma NIH Co-Investigator
- ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease Food & Drug Administration via University of Pennsylvania Medical Center Principal Investigator
- Polymorphism in Castleman’s Disease Janssen Research & Development, LLC Principal Investigator
- UARK 2003-41, A Phase II Study of High-Dose Density Therapy with Tandem Autologous Transplants for Patients with Multiple Myeloma Amgen, Inc. Principal Investigator
- UARK 2003-26, A Pilot Study of MAGE-3 and NY_ESO Immunotherapy in Combination with DT PACE Chemotherapy/Autologous Transplant in Agressive Mutliple My Celgene Principal Investigator
- UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease Chugai Biopharmaceuticals, Inc. Principal Investigator
- Potentiating Natural Killer Cell Anti-Myeloma Effects NIH Principal Investigator
- Engraftment Kinetics of Peripheral Blood Stem Cells (PBSC's) Isolated Using the Spectra Optia Apheresis System CaridianBCT Principal Investigator
- mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target NIH/Nat. Cancer Institute via University of Pennsylvania Principal Investigator
- A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to evaluate the Safety and Immunogenicity of the GSK Biologicals’ Herp GlaxoSmithKline Principal Investigator
- Phase 3 Study of Daratumumab, Bortezomib, Lenalidomide & Dexamethasone (D-VRd) + Ciltacabtagene Autoleucel vs D-VRd + Autologous Stem Cell Transplant in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients Stichting European Myeloma Network via PAREXEL International LLC Principal Investigator
- Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administered Intranodally in Multiple Myeloma Patients Leukemia & Lymphoma Society Principal Investigator
- Phase 3 Randomized, open-label clinical trial of tanespimycin (KO953) plus Bortezomib Compared to bortezomib alone in patients with multiple myeloma i Bristol-Meyers Squibb Principal Investigator
- mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target - Continuation NIH/Nat. Cancer Institute via University of Pennsylvania Principal Investigator
- 2004-04: Treatment with AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Giv AnorMED, Inc. Principal Investigator
Collaboration Network
Top Collaborators
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Showing 5 of 35 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Showing 5 of 31 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Showing 5 of 31 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Showing 5 of 25 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 11 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 10 shared publications
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Showing 5 of 10 shared publications
- Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric <scp>Castleman</scp> disease
- Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
- Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
Showing 5 of 9 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
Showing 5 of 9 shared publications
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 8 shared publications
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 8 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 7 shared publications
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics